RT Journal Article
SR Electronic
T1 SARS-CoV-2 vaccine Alpha and Delta variant breakthrough infections are rare and mild, but happen relative early after vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.23.21268324
DO 10.1101/2021.12.23.21268324
A1 Peter, Jelissa Katharina
A1 Wegner, Fanny
A1 Gsponer, Severin
A1 Helfenstein, Fabrice
A1 Roloff, Tim
A1 Tarnutzer, Rahel
A1 Grosheintz, Kerstin
A1 Back, Moritz
A1 Schaubhut, Carla
A1 Wagner, Sabina
A1 Seth-Smith, Helena
A1 Scotton, Patrick
A1 Redondo, Maurice
A1 Beckmann, Christiane
A1 Stadler, Tanja
A1 Salzmann, Andrea
A1 Kurth, Henriette
A1 Leuzinger, Karoline
A1 Bassetti, Stefano
A1 Binggisser, Roland
A1 Siegemund, Martin
A1 Weisser, Maja
A1 Battegay, Manuel
A1 Sutter, Sarah Tschudin
A1 Lebrand, Aitana
A1 Hirsch, Hans H.
A1 Fuchs, Simon
A1 Egli, Adrian
YR 2021
UL http://medrxiv.org/content/early/2021/12/24/2021.12.23.21268324.abstract
AB Introduction COVID-19 vaccines significantly reduce SARS-CoV-2 (SCoV2)-related hospitalization and mortality in randomized controlled clinical trials, as well as in real-world effectiveness against different circulating SCoV2-lineages. However, some vaccine recipients show breakthrough infection and it remains unknown, which host and viral factors contribute to this risk and how many resulted in severe outcomes. Our aim was to identify demographic and clinical risk factors for SCoV2 breakthrough infections and severe disease in fully vaccinated individuals and to compare patient characteristics in breakthrough infections caused by SCoV2 Alpha or Delta variant.Methods We conducted an exploratory retrospective case-control study from 28th of December to 25th of October 2021 dominated by the Delta SCoV2 variant. All cases of infection had to be reported by law to the local health authorities. Vaccine recipients’ data was anonymously available from the national Vaccination Monitoring Data Lake and the main local vaccine center. We compared anonymized patients’ characteristics of breakthrough infection (n=492) to two overlapping control groups including all vaccine recipients from the Canton of Basel-City (group 1 n=126’586 and group 2 n=109’382). We also compared patients with breakthrough infection caused by the Alpha to Delta variant. We used different multivariate generalized linear models (GLM).Results We found only 492/126’586 (0.39%) vaccine recipients with a breakthrough infection after vaccination during the 10 months observational period. Most cases were asymptomatic or mild (478/492 97.2%) and only very few required hospitalization (14/492, 2.8%). The time to a positive SCoV2 test shows that most breakthrough infections occurred between a few days to about 170 days after full vaccination, with a median of 78 days (interquartile range, IQR 47-124 days). Factors associated with a lower odds for breakthrough infection were: age (OR 0.987, 95%CI 0.983-0.992), previous COVID-19 infection prior to vaccination (OR 0.296, 95%CI 0.117-0.606), and (self-declared) serious side-effects from previous vaccines (OR 0.289, 95%CI 0.033-1.035). Factors associated with a higher odds for breakthrough infection were: vaccination with the Pfizer/BioNTech vaccine (OR 1.459, 95%CI 1.238-1.612), chronic disease as vaccine indication (OR 2.109, 95%CI 1.692-2.620), and healthcare workers (OR 1.404, 95%CI 1.042-1.860). We did not observe a significantly increased risk for immunosuppressed patients (OR 1.248, 95% CI 0.806-1.849).Conclusions Our study shows that breakthrough infections are rare and show mild illness, but that it occurs early after vaccination with more than 50% of cases within 70 to 80 days post-full vaccination. This clearly implies that boost vaccination should be much earlier initiated compared to the currently communicated 180-day threshold. This has important implications especially for risk groups associated with more frequent breakthrough infections such as healthcare workers, and people in high-risk care facilities. Due to changes in the epidemiological dynamic with new variants emerging, continuous monitoring of breakthrough infections is helpful to provide evidence on booster vaccines and patient groups at risk for potential complications.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of North Western Switzerland (EKNZ) gave ethical approval for this work (EKNZ numbers 2020-00769 and 2021-00774)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript. All genome sequences used are mentioned in Supplementary Table 2 with the respective accession numbers on GISAID.